iSpecimen Inc.

iSpecimen Inc.

ISPC
iSpecimen Inc.US flagNASDAQ Capital Market
3.07
USD
-0.27
- -
426,306.00Market Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
828.74
529.68
1,543.3
2,077.87
940.96
878.52
522.82
16.77
14.21
Basic EPS, GAAP
-1,008.31
-582.51
-877.26
-1,672.29
-926.81
-982.17
-703.27
-91.15
-153.56
Free Cash Flow per Basic Share
-699.11
-512.03
-262.3
-2,184.42
-545.75
-515.62
-468.19
-36.86
-89.98
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3,723.54
-3,007.44
-5,479.44
-7,094.33
-4,365.85
-5,253.05
-4,043.8
-715.7
-1,170.2
Tangible Book Value per Share
-5,852.21
-4,460.72
-7,747.54
5,053.32
1,429.7
222.09
-113.54
7.11
-27.97
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
4
4
8
11
10
10
9
2
1
Operating Margin (%)
-76.37
-90.27
-29.4
-53.21
-97.92
-112.5
-136.99
-465.42
-961.36
Depreciation Expense
- -
1
1
1
1
2
2
2
1
Net Income, GAAP
-5
-5
-5
-9
-10
-11
-12
-10
-11
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-121.67
-109.97
-56.84
-80.48
-98.5
-111.8
-134.51
-543.68
-1,080.72
Working Capital
-9
-14
-19
30
15
2
-2
1
-2
LT Debt
- -
- -
- -
3
- -
- -
- -
- -
- -
Total Equity
-18
-23
-27
30
20
10
3
3
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
1
Market Capitalization
- -
- -
- -

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4
7
3
Cash, Cash Equivalents & STI
3
7
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
6
6
Payables & Accruals
5
6
5
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-73.16%
-6.73%
Free Cash Flow
- -
136.69%
-49.03%
Net Income, GAAP
- -
22.36%
-16.09%
Sales/Revenue/Turnover
- -
-12.15%
-79.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
3
3
1
9
2025
1
1
- -
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-254.24
-148.78
-83.82
- -
-703.27
2025
-28.55
-16.78
-19.05
- -
-91.15
2026
-266.61
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Katharyn Field
Full Time Employees
24
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
450 Bedford Street Woburn MA United States of America 02420
IPO Date
Jun 17, 2021
Business
iSpecimen Inc. (Nasdaq: ISPC) operates an online marketplace that connects life science researchers worldwide with healthcare providers offering human biospecimens, including biofluids such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissues comprising fresh, fixed, cryopreserved tissue, formalin-fixed paraffin-embedded blocks, slides, and curls; and hematopoietic stem and immune cells from bone marrow, cord blood, whole blood, or sub-components like peripheral blood mononuclear cells and other isolated cell types. The proprietary iSpecimen Marketplace platform facilitates search, workflow, data management, compliance, and reporting functions, while the company handles marketing, sales, contracting, and quality control services such as centrifugation, custom aliquoting, specimen testing including PBMC isolation and sequencing, slide preparation, and pathology assessments. Founded in 2009 by pathologists and headquartered in Lexington, Massachusetts, with additional facilities in Woburn, Massachusetts, iSpecimen serves researchers in industry, academia, and government across the Americas, Europe, Middle East, Africa, and Asia Pacific, primarily generating revenue from the Americas. In August 2025, iSpecimen closed a $1.75 million private placement priced at-the-market under Nasdaq rules, issuing 1,559,828 shares of common stock and pre-funded warrants to accredited investors, with $500,000 allocated to marketing and advertising services through IR Agency LLC and the balance for working capital and general corporate purposes; WestPark Capital acted as exclusive placement agent. Earlier in July 2025, the company priced a $4 million underwritten public offering at $0.70 per share, including 5.7 million shares, with proceeds designated for $1.5 million in marketing via IR Agency LLC, $1 million milestone payment to Sales Stack Solutions Corp., and general corporate needs. In September 2025, iSpecimen announced plans to establish a corporate treasury reserve of up to $200 million centered on the Solana blockchain ecosystem through collaborations with WestPark Capital and BlockArrow, marking a strategic shift toward decentralized infrastructure and digital assets to enhance technological leadership in life sciences. These funding initiatives and treasury strategy reflect ongoing efforts to fuel marketing expansion, operational milestones, and innovative financial positioning amid revenue growth with a 6-year CAGR of 59%.

Company News

APIChat
  • E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement

  • E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement

  • iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement

  • iSpecimen Announces 1-for-40 Reverse Stock Split

  • Why iSpecimen Shares Are Surging On Friday?

  • Analyzing Agilon Health (NYSE:AGL) & iSpecimen (NASDAQ:ISPC)

  • iSpecimen Is Trending Overnight — Here's Why ISPC Stock Surged 56% In The After-Hours Session

  • iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time

  • Critical Survey: iSpecimen (NASDAQ:ISPC) vs. Progyny (NASDAQ:PGNY)

  • Head to Head Survey: iSpecimen (NASDAQ:ISPC) & XWELL (NASDAQ:XWEL)

  • iSpecimen Achieves Rapid Procurement Milestone for Influenza Research

  • iSpecimen (ISPC) Stock Rockets 43% After Hours — Here's Why It's Trending

  • iSpecimen Launches AI Agent Revolutionizing Biospecimen Matching

  • iSpecimen Launches AI Agent Revolutionizing Biospecimen Matching

  • iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete

  • iSpecimen Achieves Rapid Procurement Milestone for Influenza Research

  • E.F. Hutton & Co. Acts as Exclusive Placement Agent in iSpecimen Inc.'s ~$5.5 Million Private Placement

  • Stock Market Today: S&P 500, Dow Jones Futures Down As Santa Rally Hopes Fade—Investors Await Initial Jobless Claims Report

  • iSpecimen Inc (ISPC) Stock Surged 42% After-Hours: Here's The News Behind The Move

  • iSpecimen Inc. Announces Pricing of ~$5.5 Million Private Placement